Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April July May June August September October November December
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

UFS leads the way with GMO testing
2003-08-25

A formal agreement linking Africa’s first testing facility for genetically modified organisms (GMO) to an international organization was signed at the University of the Free State.

According to the manager of the GMO testing facility, Dr Chris Viljoen of the Department of Plant Sciences, the facility is now part of GeneScan, a world leader in food diagnostic testing, which has its headquarters in Germany with subsidiaries in the Unites States, Brazil and Hong Kong.

The facility at the UFS has been selected by the second largest international food company to do all its South African GMO testing for export products.

The GMO testing facility is the brainchild of Dr Viljoen, who is a specialist in the field of marker biotechnology and its applications in crop science.

He says the need for such a testing facility arose due to the international regulations on GMOs in food, especially Europe and Asia that requires South African exporters to certify whether their products contain any GMO.

“The regulations in Europe and Asia reflect a consumer need for choice in what they eat due to concerns over the safety of GMOs, as well as environmental and ethical issues. GMO testing and labelling allow consumers the right of choice to eat genetically modified foods or not. According to EU regulations, any product with a GMO content of 1% or higher is labelled as containing GMO.”

According to Dr Viljoen only four products in South Africa are currently GMO. They are white and yellow maize that have been made insect resistant, soya bean that is herbicide tolerant and insect resistant cotton. He says that the awareness of GMOs among South Africans is still very limited, especially in poorer communities, but it is likely to increase with the efforts being made in consumer education by government, seed companies and NGOs.

The testing facility has been established to accommodate the local as well as international market. The GMO testing at the UFS facility is performed using real time PCR, the most advanced means of GMO detection currently available, and using GeneScan developed technology that is recognized worldwide.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept